500 related articles for article (PubMed ID: 8356589)
21. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
22. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
[TBL] [Abstract][Full Text] [Related]
24. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
25. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
26. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
27. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
28. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
[TBL] [Abstract][Full Text] [Related]
29. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
30. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.
Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda R; Habu S; Nishimura T
Bone Marrow Transplant; 1995 Feb; 15(2):193-8. PubMed ID: 7773208
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3.
Platts KE; Lawry J; Hancock BW; Rees RC
Exp Cell Res; 1993 Sep; 208(1):154-60. PubMed ID: 8359215
[TBL] [Abstract][Full Text] [Related]
33. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
34. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.
Katsanis E; Xu Z; Anderson PM; Dancisak BB; Bausero MA; Weisdorf DJ; Blazar BR; Ochoa AC
Bone Marrow Transplant; 1994 Oct; 14(4):563-72. PubMed ID: 7858530
[TBL] [Abstract][Full Text] [Related]
35. A VLA-4 alpha-chain specific monoclonal antibody enhances CD3-induced IL-2/IL-2 receptor-dependent T-cell proliferation.
Udagawa T; McIntyre BW
Lymphokine Cytokine Res; 1992 Oct; 11(5):193-9. PubMed ID: 1467362
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
[TBL] [Abstract][Full Text] [Related]
37. [Effect of autologous dendritic cells on chronic myeloid leukemia cells in vitro].
Li Y; Yang Y; Li S; Meng W; Ding X; Wu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):47-50. PubMed ID: 15600177
[TBL] [Abstract][Full Text] [Related]
38. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
39. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
40. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
